KMPHARMACEUTICAL Co.,Ltd.

KOSDAQ:A225430 Stock Report

Market Cap: ₩14.7b

KMPHARMACEUTICALLtd Past Earnings Performance

Past criteria checks 0/6

KMPHARMACEUTICALLtd's earnings have been declining at an average annual rate of -35.6%, while the Personal Products industry saw earnings growing at 23.8% annually. Revenues have been declining at an average rate of 9.1% per year.

Key information

-35.57%

Earnings growth rate

-34.90%

EPS growth rate

Personal Products Industry Growth3.77%
Revenue growth rate-9.13%
Return on equity-14.50%
Net Margin-24.29%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article Feb 06

Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Revenue & Expenses Breakdown

How KMPHARMACEUTICALLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A225430 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2616,379-3,9786,202899
31 Dec 2515,990-3,9685,975944
30 Sep 2515,093-4,6786,044837
30 Jun 2514,015-4,6125,802719
31 Mar 2514,088-4,8816,407628
31 Dec 2414,475-4,5736,392560
30 Sep 2414,545-3,6486,072478
30 Jun 2415,295-3,2086,051397
31 Mar 2417,095-1,8175,391337
31 Dec 2317,770-1,3205,230298
30 Sep 2317,580-2,7766,871321
30 Jun 2317,711-3,2666,434376
31 Mar 2316,044-3,9056,055414
31 Dec 2215,631-3,9255,996450
30 Sep 2218,805-1,8643,917492
30 Jun 2220,000-1,2713,987473
31 Mar 2222,043-6704,252445
31 Dec 2122,705-6114,014405
30 Sep 2121,335-2293,561320
30 Jun 2121,164-153,789277
31 Mar 2122,518734,016272
31 Dec 2022,9284714,371307
30 Sep 2022,844-5125,826371
30 Jun 2023,443-5526,625304
31 Mar 2021,326-6126,349421
31 Dec 1920,338-9026,534368
30 Sep 1919,7312335,647291
30 Jun 1918,406-12,3194,489291
31 Mar 1917,477-12,5614,537158
31 Dec 1817,302-12,3303,810178
30 Sep 1816,654-12,0043,264161
31 Dec 1716,9151,7523,173100

Quality Earnings: A225430 is currently unprofitable.

Growing Profit Margin: A225430 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A225430 is unprofitable, and losses have increased over the past 5 years at a rate of 35.6% per year.

Accelerating Growth: Unable to compare A225430's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A225430 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.8%).


Return on Equity

High ROE: A225430 has a negative Return on Equity (-14.5%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/04 17:33
End of Day Share Price 2026/06/04 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KMPHARMACEUTICAL Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.